|Articles|June 8, 2022
Tissue IHC: Translating Technology into Patient Testing After Biomarker Target is ID
Author(s)Frontage Laboratories, Inc.
In the discovery and investigation of novel biomarkers, tissue immunohistochemistry (IHC) studies are critical, but how do you translate the technology into the clinical laboratory for patient testing once a biomarker target has been identified?
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Content
Trending on Applied Clinical Trials Online
1
What Patients Want from Remote Trials: New Survey Data Reveals Preferences Around Usability, Trust, and Participation
2
FDA Approves GSK’s Exdensur for Severe Asthma Based on SWIFT Phase III Data
3
ACT Brief: Patient Preferences in Remote Trials, Sanofi’s Neurology and Immunology Deals, and AI-Driven Biomarkers in Oncology
4
Rethinking Operational Models to Reduce Site Burden in 2026
5